ReviewBioMed research international2014
Prognostic histopathological and molecular markers on prostate cancer needle-biopsies: a review.
Review in BioMed research international, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed.
- KLS-3021, a multifunctional oncolytic virus, demonstrates potent early-intervention efficacy in preclinical models of prostate-confined and locally advanced prostate cancer.Frontiers in oncology · 2026Article
- Article
- Exploring the efficacy of AMACR, ERG, and AR immunostains in prostatic adenocarcinoma and their association with novel grade groups.European journal of histochemistry : EJH · 2025Article
- Prostate Cancer Scoring Index for Risk of Progression of Radioresistant Disease.Journal of personalized medicine · 2023Article
- Article
- Machine learning-based radiomics for multiple primary prostate cancer biological characteristics prediction withLa Radiologia medica · 2022Article
- Multiparametric MRI and Machine Learning Based Radiomic Models for Preoperative Prediction of Multiple Biological Characteristics in Prostate Cancer.Frontiers in oncology · 2022Article
- Tumor B7-H3 expression in diagnostic biopsy specimens and survival in patients with metastatic prostate cancer.Prostate cancer and prostatic diseases · 2021Article
- Immunohistochemical investigation of cytokine expression levels as biomarkers in transrectal ultrasound-guided needle biopsy specimens of prostate adenocarcinoma.Molecular and clinical oncology · 2021Article
- Role of AI and Histopathological Images in Detecting Prostate Cancer: A Survey.Sensors (Basel, Switzerland) · 2021Review
- Expression of ERBB Family Members as Predictive Markers of Prostate Cancer Progression and Mortality.Cancers · 2021Article
- Diagnostic utility of a-methylacyl COA racemase in prostate cancer of the Iranian population.Journal of research in medical sciences : the official journal of Isfahan University of Medical Sciences · 2021Article
- Article
- Association of polymorphisms of PTEN, AKT1, PI3K, AR, and AMACR genes in patients with prostate cancer.Genetics and molecular biology · 2020Article
- The Role of AMACR, CD10, TMPRSS2-ERG, and p27 Protein Expression Among Different Gleason Grades of Prostatic Adenocarcinoma on Needle Biopsy.Clinical Medicine Insights. Oncology · 2020Article
- The Value of Prostate-Specific Antigen-Related Indexes and Imaging Screening in the Diagnosis of Prostate Cancer.Cancer management and research · 2020Article
- Ki-67 is an independent predictor of prostate cancer death in routine needle biopsy samples: proving utility for routine assessments.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2019Article
- Specific and reliable detection of Myosin 1C isoform A by RTqPCR in prostate cancer cells.PeerJ · 2018Article
- In prostate cancer needle biopsies, detections of PTEN loss by fluorescence in situ hybridization (FISH) and by immunohistochemistry (IHC) are concordant and show consistent association with upgrading.Virchows Archiv : an international journal of pathology · 2016Article
- A multicenter study shows PTEN deletion is strongly associated with seminal vesicle involvement and extracapsular extension in localized prostate cancer.The Prostate · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Prostate cancer is diverse in clinical presentation, histopathological tumor growth patterns, and survival. Therefore, individual assessment of a tumor's aggressive potential is crucial for clinical decision-making in men with prostate cancer. To date a large number of prognostic markers for prostate cancer have been described, most of them based on radical prostatectomy specimens. However, in order to affect clinical decision-making, validation of respective markers in pretreatment diagnostic needle-biopsies is essential. Here, we discuss established and promising histopathological and molecular parameters in diagnostic needle-biopsies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.